Clinical Trials
487 trialsKEYNOTE145
Acerta Pharma BV
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
University of Washington
Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
City of Hope Medical Center
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
Mayo Clinic
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
National Institutes of Health Clinical Center (CC)
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
Calibr, a division of Scripps Research
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
University of Chicago
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
BeOne Medicines
CS22-03
AIDS Malignancy Consortium
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Eli Lilly and Company
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
H. Lee Moffitt Cancer Center and Research Institute
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies
BeOne Medicines
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
University of Arizona
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Thomas Jefferson University
ELM-1
Regeneron Pharmaceuticals
BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
Boryung Pharmaceutical Co., Ltd
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Masonic Cancer Center, University of Minnesota
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
University of Maryland, Baltimore
Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
Masonic Cancer Center, University of Minnesota
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
University of California, Davis
Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood
M.D. Anderson Cancer Center
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
Fred Hutchinson Cancer Center
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
Ipsen
Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Off the Beaten Track" Liquid Biopsy
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)
Boehringer Ingelheim
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas
Stanford University
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
Xencor, Inc.
ILyAD
University of Rochester
Bendamustine Plus Rituximab Versus CHOP Plus Rituximab
University of Giessen
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
Calibr, a division of Scripps Research
AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders
City of Hope Medical Center
Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy
Pack Health
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma
City of Hope Medical Center
A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan
City of Hope Medical Center
PROSECO
University Hospital Southampton NHS Foundation Trust
Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
Eastern Cooperative Oncology Group
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
City of Hope Medical Center
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
Mayo Clinic
Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma
University of Nebraska
Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
University of Nebraska
Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation
University of Nebraska
CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies
M.D. Anderson Cancer Center
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
Stanford University
FUSION NHL 001
Celgene
Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin
University of Nebraska